-transparent.png){kind=logo}
Thirty-one postmenopausal patients with advanced breast cancer either unresponsive to tamoxifen or progressing after responding to tamoxifen were treated with aminoglutethimide (1 000 - 1 250 mg/d) plus hydrocortisone replacement. The response rate was 33% in patients who had never responded to tamoxifen and 47% in patients who had previously responded to tamoxifen. The overall response rate was 42%. These results show that aminoglutethimide is an effective second-line hormonal treatment for patients with advanced breast cancer.
Related Publications
W R Bezwoda, and
D P Derman, and
S Browde, and
G Goss, and
M Lange
November 1982,
Cancer,
W R Bezwoda, and
D P Derman, and
S Browde, and
G Goss, and
M Lange
October 1992,
Gan to kagaku ryoho. Cancer & chemotherapy,
W R Bezwoda, and
D P Derman, and
S Browde, and
G Goss, and
M Lange
January 1982,
The Medical journal of Australia,
W R Bezwoda, and
D P Derman, and
S Browde, and
G Goss, and
M Lange
May 1983,
British medical journal (Clinical research ed.),
W R Bezwoda, and
D P Derman, and
S Browde, and
G Goss, and
M Lange
August 1982,
Cancer research,
W R Bezwoda, and
D P Derman, and
S Browde, and
G Goss, and
M Lange
December 1984,
Harefuah,
W R Bezwoda, and
D P Derman, and
S Browde, and
G Goss, and
M Lange
August 1982,
Cancer research,
W R Bezwoda, and
D P Derman, and
S Browde, and
G Goss, and
M Lange
August 1985,
Southern medical journal,
W R Bezwoda, and
D P Derman, and
S Browde, and
G Goss, and
M Lange
November 1984,
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
W R Bezwoda, and
D P Derman, and
S Browde, and
G Goss, and
M Lange
January 1988,
Oncology,
